[A24-46] Pembrolizumab (NSCLC, neoadjuvant + adjuvant) – Benefit assessment according to § 35a Social Code Book V
Last updated 17.10.2024
Project no.:
A24-46
Commission:
Commission awarded on 30.04.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adults with resectable non-small cell lung cancer
Result of dossier assessment:
- Patients with tumour cell PD-L1 expression ≥ 1% at high risk of recurrence; neoadjuvant and adjuvant treatment: added benefit not proven
- Patients with tumour cell PD-L1 expression < 1% at high risk of recurrence; neoadjuvant and adjuvant treatment: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A24-46_en
Federal Joint Committee (G-BA)
17-10-2024 A G-BA decision was published.
G-BA documents on this decision